Orbimed Advisors Llc Buys Tricida Inc, Anthem Inc, Allergan PLC, Sells Regeneron Pharmaceuticals Inc, ARMO BioSciences Inc, AbbVie Inc

• New Purchases: TCDA, ANTM, INSP, TNDM, EXEL, UNH, VRCA, INCY, HUM, ARPO,
• Added Positions: AGN, XRAY, ASND, MYL, TMO, BIIB, JNJ, CRSP, ZLAB, BLUE,
• Reduced Positions: REGN, THC, BMY, A, AMGN, GBT, LOXO, SHPG, UHS, MGLN,
• Sold Out: ARMO, ABBV, EVHC, XNCR, MCRB, NVLN,

For the details of ORBIMED ADVISORS LLC's stock buys and sells, go to http://www.gurufocus.com/StockBuy.php?GuruName=ORBIMED+ADVISORS+LLC

1. Alexion Pharmaceuticals Inc (ALXN) - 3,124,603 shares, 4.66% of the total portfolio. Shares reduced by 4.4%
2. Biogen Inc (BIIB) - 1,167,900 shares, 4.08% of the total portfolio. Shares added by 12.25%
3. Tricida Inc (TCDA) - 10,889,280 shares, 3.92% of the total portfolio. New Position
4. Boston Scientific Corp (BSX) - 9,574,695 shares, 3.76% of the total portfolio. Shares reduced by 7.74%
5. Vertex Pharmaceuticals Inc (VRTX) - 1,792,600 shares, 3.66% of the total portfolio. Shares reduced by 3.34%

Orbimed Advisors Llc initiated holding in Tricida Inc. The purchase prices were between $26 and $29.9, with an estimated average price of $27.95. The stock is now traded at around $23.46. The impact to a portfolio due to this purchase was 3.92%. The holding were 10,889,280 shares as of 2018-06-30.

Orbimed Advisors Llc initiated holding in Anthem Inc. The purchase prices were between $220.13 and $245.16, with an estimated average price of $231.73. The stock is now traded at around $264.17. The impact to a portfolio due to this purchase was 1.52%. The holding were 531,800 shares as of 2018-06-30.

Orbimed Advisors Llc initiated holding in Inspire Medical Systems Inc. The purchase prices were between $24.05 and $39.5, with an estimated average price of $32.33. The stock is now traded at around $49.62. The impact to a portfolio due to this purchase was 1.05%. The holding were 2,444,221 shares as of 2018-06-30.

Orbimed Advisors Llc initiated holding in Tandem Diabetes Care Inc. The purchase prices were between $4.9 and $23.64, with an estimated average price of $12.27. The stock is now traded at around $33.03. The impact to a portfolio due to this purchase was 0.45%. The holding were 1,689,000 shares as of 2018-06-30.

Orbimed Advisors Llc initiated holding in Exelixis Inc. The purchase prices were between $18.56 and $22.45, with an estimated average price of $20.68. The stock is now traded at around $19.41. The impact to a portfolio due to this purchase was 0.44%. The holding were 1,681,200 shares as of 2018-06-30.

Orbimed Advisors Llc initiated holding in UnitedHealth Group Inc. The purchase prices were between $217.2 and $255.98, with an estimated average price of $240.1. The stock is now traded at around $260.61. The impact to a portfolio due to this purchase was 0.36%. The holding were 123,300 shares as of 2018-06-30.

Orbimed Advisors Llc added to a holding in Allergan PLC by 85.44%. The purchase prices were between $143.8 and $175.19, with an estimated average price of $160.7. The stock is now traded at around $184.48. The impact to a portfolio due to this purchase was 1.19%. The holding were 1,286,205 shares as of 2018-06-30.

Orbimed Advisors Llc added to a holding in Dentsply Sirona Inc by 963.78%. The purchase prices were between $42.29 and $50.64, with an estimated average price of $47.02. The stock is now traded at around $37.97. The impact to a portfolio due to this purchase was 1.14%. The holding were 2,393,500 shares as of 2018-06-30.

Orbimed Advisors Llc added to a holding in Ascendis Pharma A/S by 31.06%. The purchase prices were between $58.55 and $73.92, with an estimated average price of $65.67. The stock is now traded at around $67.36. The impact to a portfolio due to this purchase was 0.84%. The holding were 4,413,291 shares as of 2018-06-30.

Orbimed Advisors Llc added to a holding in Mylan NV by 101.86%. The purchase prices were between $35.37 and $41.86, with an estimated average price of $39.24. The stock is now traded at around $37.82. The impact to a portfolio due to this purchase was 0.81%. The holding were 3,702,800 shares as of 2018-06-30.

Orbimed Advisors Llc added to a holding in Thermo Fisher Scientific Inc by 49.85%. The purchase prices were between $203.14 and $219.53, with an estimated average price of $212.33. The stock is now traded at around $229.00. The impact to a portfolio due to this purchase was 0.48%. The holding were 583,500 shares as of 2018-06-30.

Orbimed Advisors Llc added to a holding in Johnson & Johnson by 62.48%. The purchase prices were between $119.4 and $131.76, with an estimated average price of $124.84. The stock is now traded at around $130.43. The impact to a portfolio due to this purchase was 0.42%. The holding were 756,000 shares as of 2018-06-30.

Orbimed Advisors Llc sold out a holding in ARMO BioSciences Inc. The sale prices were between $25.68 and $50.05, with an estimated average price of $41.01.

Orbimed Advisors Llc sold out a holding in AbbVie Inc. The sale prices were between $89.78 and $106.23, with an estimated average price of $97.64.

Orbimed Advisors Llc sold out a holding in Envision Healthcare Corp. The sale prices were between $35.83 and $44.78, with an estimated average price of $41.05.

Orbimed Advisors Llc sold out a holding in Xencor Inc. The sale prices were between $28.41 and $42.41, with an estimated average price of $34.37.

Orbimed Advisors Llc sold out a holding in Seres Therapeutics Inc. The sale prices were between $6.91 and $9.55, with an estimated average price of $8.17.

Orbimed Advisors Llc sold out a holding in Novelion Therapeutics Inc. The sale prices were between $3.28 and $4.49, with an estimated average price of $4.02.

Orbimed Advisors Llc reduced to a holding in Regeneron Pharmaceuticals Inc by 61.31%. The sale prices were between $284.6 and $344.99, with an estimated average price of $312.95. The stock is now traded at around $361.87. The impact to a portfolio due to this sale was -2.54%. Orbimed Advisors Llc still held 372,500 shares as of 2018-06-30.

Orbimed Advisors Llc reduced to a holding in Tenet Healthcare Corp by 91.1%. The sale prices were between $22.9 and $38.35, with an estimated average price of $31.02. The stock is now traded at around $33.09. The impact to a portfolio due to this sale was -1.16%. Orbimed Advisors Llc still held 372,900 shares as of 2018-06-30.

Orbimed Advisors Llc reduced to a holding in Bristol-Myers Squibb Company by 35.24%. The sale prices were between $50.53 and $62.98, with an estimated average price of $54.03. The stock is now traded at around $60.26. The impact to a portfolio due to this sale was -1.03%. Orbimed Advisors Llc still held 2,380,300 shares as of 2018-06-30.

Orbimed Advisors Llc reduced to a holding in Agilent Technologies Inc by 33.55%. The sale prices were between $61.14 and $69.55, with an estimated average price of $65.3. The stock is now traded at around $64.73. The impact to a portfolio due to this sale was -0.8%. Orbimed Advisors Llc still held 1,885,100 shares as of 2018-06-30.

Orbimed Advisors Llc reduced to a holding in Amgen Inc by 72.13%. The sale prices were between $166.05 and $186.51, with an estimated average price of $176.84. The stock is now traded at around $195.26. The impact to a portfolio due to this sale was -0.69%. Orbimed Advisors Llc still held 124,100 shares as of 2018-06-30.

Orbimed Advisors Llc reduced to a holding in Global Blood Therapeutics Inc by 69.5%. The sale prices were between $38.7 and $50.15, with an estimated average price of $45.49. The stock is now traded at around $47.95. The impact to a portfolio due to this sale was -0.62%. Orbimed Advisors Llc still held 447,275 shares as of 2018-06-30.